Industry News
-
CagriSema’s clinical acceleration of weight loss in China
On July 5, Novo Nordisk launched a phase III clinical trial of CagriSema injection in China, the purpose of which is to compare the safety and efficacy of CagriSema injection with semeglutide in obese and overweight patients in China. CagriSema injection is a long-acting...Read more
